Press release
c-MET NSCLC Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape. Click here to read more @ c-MET-NSCLC Pipeline Outlook [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the c-MET-NSCLC Pipeline Report
* In March 2025, Merus N.V announced a phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naive or have progressed after receiving prior therapy for advanced/metastatic disease.
* In March 2025, AbbVie conducted a phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
* In March 2025, Betta Pharmaceuticals Co., Ltd. organized a phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.
* In March 2025, Beijing Pearl Biotechnology Limited Liability Company conducted a phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.
* In January 2025:- AbbVie conducted a Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
* DelveInsight's c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment.
* The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis , and others.
* Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib , and others.
Stay informed about the cutting-edge advancements in c-MET NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
c-MET NSCLC Emerging Drugs Profile
* JNJ-61186372: Janssen Research & Development, LLC
JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen's licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.
* PLB1001 - Beijing Pearl Biotechnology Limited Liability Company
PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
Learn more about c-MET NSCLC Drugs opportunities in our groundbreaking c-MET NSCLC Research and development projects @ c-MET NSCLC Unmet Needs [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
c-MET NSCLC Companies
AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intramuscular
* Intratumoral
* Intravenous
* Molecule Type
c-MET NSCLC Products have been categorized under various Molecule types such as
* Gene therapies
* Bispecific antibodies
* Immunotherapies
* Monoclonal antibodies
* Small molecules
* Product Type
Discover the latest advancements in c-MET NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the c-MET NSCLC Pipeline Report
* Coverage- Global
* c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis , and others.
* C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib , and others.
* c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
* Mid Stage Products (Phase II)
* Telisotuzumab: AbbVie
* PLB1001: Beijing Pearl Biotechnology Limited Liability Company
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* JNJ-61186372: Janssen Research & Development, LLC
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cmet-nsclc-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release c-MET NSCLC Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3954767 • Views: …
More Releases from ABNewswire
Shoulder Replacement Market Poised for Transformative Growth by 2030: Market Dri …
The shoulder replacement devices market is experiencing robust growth, fueled by an aging population, increasing prevalence of shoulder disorders, technological advancements by leading shoulder prosthesis manufacturers, including Zimmer Biomet, Johnson & Johnson, Wright Medical Group (acquired by Stryker), Scripps Health, Smith & Nephew, and Arthrex in implant design, and growing adoption of reverse shoulder arthroplasty procedures.
DelveInsight's "Shoulder Replacement Devices - Global Market Insights, Competitive Landscape, and Market Forecast - 2030…
Inflammatory Breast Cancer Market Expected to Experience Substantial Growth by 2 …
The inflammatory breast cancer market is poised for significant growth with a promising pipeline of emerging therapies targeting this rare but aggressive disease. Key breast cancer companies, including Merck, AstraZeneca, Gilead Sciences, Daiichi Sankyo, Pfizer, and several others, are actively developing innovative treatments to address the high unmet needs in inflammatory breast cancer management.
DelveInsight's "Inflammatory Breast Cancer - Market Insight, Epidemiology And Market Forecast [https://www.delveinsight.com/report-store/inflammatory-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding…
Bone Resorption Market Expected to Grow Significantly by 2032: Market Opportunit …
The bone resorption market is poised for substantial transformation, driven by the rising prevalence of osteoporosis and related disorders, an aging population, and significant advancements in targeted therapies. Key bone resorption companies, including Bioventus, Isto Biologics, Locate Bio, Kuros Biosciences, OssDsign, BONESUPPORT, Cerapedics, DiscGenics, Osteopore, TherageniX, Stryker, DePuy Synthes, Medtronic, Zimmer Biomet, and Orthofix, among others, are innovating in this landscape.
DelveInsight's "Bone Resorption - Market Insight, Epidemiology and Market Forecast…
Metastatic HR+/HER2- Breast Cancer Market Projected to Expand Significantly by 2 …
The metastatic HR+/HER2- breast cancer market is experiencing robust growth, fueled by an increasing patient pool and the introduction of innovative targeted therapies. Key breast cancer companies, such as Pfizer, Novartis, AstraZeneca, Roche, Arvinas, Olema Pharmaceuticals, Eli Lilly, and others, are shaping the treatment landscape for this most prevalent subtype of breast cancer.
DelveInsight's "Metastatic HR+/HER2- Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into the…
More Releases for MET
I Met Jesus Presented By RISING STAR
RISING STAR, the innovative fashion house based in New York City, presents the timeless art collection, entitled I Met Jesus.
I Met Jesus, includes several limited subcollections, I Met Jesus 5 Times This Year and He Named My Brand, I Met Jesus 5 Times Again...3 Times in January and I Met Jesus 10 Times. In total, the collection contains just over 100 photographs, which have received individual listings that range…
Global Potassium Met Bisulfite Market Research
Global Potassium Met Bisulfite Market advertise is foreseen to develop at a CAGR of 4.56% in the determined year. The interest for potassium metabisulfite is significantly determined by development in the interest for wine and brew fabricating enterprises. Likewise, the development of the nourishment additives industry is moreover driving the development of Global Potassium Met Bisulfite Market in nations with strict direction on non-sustenance synthetic compounds utilized in nourishment and…
Het Beveiligen Van uw Bedrijf met Arbeidsongeschiktheidsverzekering Vergelijken
Het vergelijken van arbeidsongeschiktheidsverzekeringen is een frequent hulpmiddel om te bepalen wat je het meeste baten mogelijk met uw geïnvesteerde premies. Niet alleen springen in een applicatie, omdat het voorspelt ruime vergoedingen en niet-belastbare terugbetaling. U kunt op dit moment beseffen dat je in feite meer betalen aan de superieure behouden, dan profiteren van de voordelen waarmee je vooral kocht de arbeidsongeschiktheidsverzekering voor.
Wanneer u Arbeidsongeschiktheidsverzekering vergelijken, loopt u het risico…
Met Office Launch Eco T-Shirt Range
The Met Office has teamed up with Rapanui, an eco-fashion company, to create a range of weather related T-shirts just in time for summer.
The Met Office eco clothing collection is made from organic cotton in an ethical, wind powered factory and features a range of weather related designs inspired by the imagery, science and history of the Met Office.
Mart Drake-Knight co-founder of Rapanui said:
“The Met Office is the international…
When Cleankill met Sarah Beeny
Staff from Surrey-based Cleankill Pest Control are celebrating after appearing on national television.
The pest experts were thrilled when they were contacted recently by well-known TV presenter Sarah Beeny to solve a clothes moth problem in a London woman’s house.
Sarah asked Cleankill to help architect Kate Grose whose clothes were being eaten away in her two-bed maisonette. Cleankill Managing Director Paul Bates was filmed showing where to look…
Met Office launches interactive 4C climate change map
The Met Office unveils Interactive map to illustrate a 4C temperatures rise by 2060, reports Envido.
The Met Office launched yesterday a new interactive map designed to illustrate the impact of climate change with an average global temperature rise of 4C.
The interactive map follows the release last month of new research saying that the catastrophic increase in temperature could occur as early as 2060 if global GHG emissions do not peak…
